|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
|
|
|
ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
|
|
|
ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
|
|
|
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
|
|
|
ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
|
|
|
ACADIA Pharmaceuticals Added to Russell 2000 Index
|
|
|
ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
|
|
|
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
|
|
|
ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
|
|
|
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
|
|
|
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
|
ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
|
|
|
ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
|
|
|
ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
|
|
|
ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
|
|
|
ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
|
|
|
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
|
|
|
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
|
|
|
ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
|
|
|
ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
|
